Improved Urinary Cortisol Metabolome in Addison Disease: A Prospective Trial of Dual-Release Hydrocortisone.

ABSTRACT:

Context

Oral once-daily dual-release hydrocortisone (DR-HC) replacement therapy has demonstrated an improved metabolic profile compared to conventional 3-times-daily (TID-HC) therapy among patients with primary adrenal insufficiency. This effect might be related to a more physiological cortisol profile, but also to a modified pattern of cortisol metabolism.

Objective

This work aimed to study cortisol metabolism during DR-HC and TID-HC.

Design

A randomized, 12-week, crossover study was conducted.

Intervention and participants

DC-HC and same daily dose of TID-HC were administered to patients with primary adrenal insufficiency (n = 50) vs healthy individuals (n = 124) as controls.

Main outcome measures

Urinary corticosteroid metabolites were measured by gas

SUBMITTER: Espiard S 

PROVIDER: S-EPMC7947853 | biostudies-literature | 2021 Mar

REPOSITORIES: biostudies-literature